Donor selection based on NK alloreactivity for patients with hematological malignancies

Area of Science:

• Immunology
• Oncology
• Hematology

Background:

• Natural killer (NK) cells are vital immune cells that defend against infections and tumors.
• NK cell activity is modulated by inhibitory and activating receptors, including killer immunoglobulin-like receptors (KIR) and CD94/NKG2A, which interact with human leukocyte antigen (HLA) Class I molecules.
• NK cell function is essential for the graft-versus-leukemia (GVL) effect, a key mechanism in hematopoietic stem cell transplantation (HCT).

Purpose of the Study:

• To review NK cell functions, their receptors and ligands.
• To discuss therapeutic strategies utilizing NK cells in HCT for hematological malignancies.
• To provide insights into controversial results and enhance understanding of alloreactive NK cell donor selection in HCT.

Main Methods:

• Review of existing literature on NK cell biology and function in HCT.
• Analysis of therapeutic approaches including adoptive NK cell transfer, CAR-NK cells, and antibody-based therapies.
• Discussion of NK cell receptor-ligand interactions and their role in NK cell licensing and anti-tumor activity.

Main Results:

• NK cells play a significant role in improving HCT survival by reducing relapse mortality via the GVL effect.
• Therapeutic strategies targeting NK cells are actively being developed and utilized for hematological malignancies.
• Alloreactive NK cell selection algorithms are crucial for optimizing HCT outcomes.

Conclusions:

• NK cell-mediated GVL effect is a critical component of successful HCT for hematological malignancies.
• Optimizing alloreactive NK cell donor selection is essential for maximizing therapeutic benefits and minimizing relapse.
• Further research and understanding of NK cell biology and selection strategies can improve HCT efficacy.